Sponsor

Spanish Breast Cancer Research Group

Clinical research sponsor

How to interpret these research links

Connected source records

The exact organization name Spanish Breast Cancer Research Group appears in 54 distinct published trial records. The links retain registry-reported sponsor and collaborator roles; differently spelled legal entities are not automatically merged. Recruiting status describes the current published registry snapshot, not an independently verified availability guarantee.

Data basis: current published ClinicalTrials.gov records and, where present, RxNorm, MONDO and FDA-label identifiers. See the evidence interpretation and counting methodology.

Published trials54
Recruiting shown3
Roles2
SourceClinicalTrials.gov
Advertisement

Clinical trials

54 shown
Impact of Exercise on Quality of Life of EBC Patients on Treatment With Adjuvant AI With or Without CDK4/6 InhibitorsNCT07215364 · lead sponsor · 2026-07-02
RECRUITING
Long-Term Follow-up Study of Early Stage Breast Cancer Patients Included in GEICAM StudiesNCT03390894 · lead sponsor · 2018-01-18
RECRUITING
A Prospective Registry Study in Patients With Unresectable Locally Advanced or Metastatic Breast Cancer (MBC)NCT02819882 · lead sponsor · 2016-08-01
RECRUITING
neoAGORA: Exploring Clinical Utility of Serial Liquid Biopsy (ctDNA) in Patients With Early-Stage Breast CancerNCT07718841 · lead sponsor · 2026-08-01
NOT_YET_RECRUITING
Study on the Level of Physical Activity in Patients Diagnosed With Breast Cancer in SpainNCT07478939 · lead sponsor · 2025-01-08
COMPLETED
Trastuzumab Deruxtecan in First-line HER2-positive Locally Advanced/MBC Patients Resistant to Trastuzumab+PertuzumabNCT05744375 · lead sponsor · 2023-09-28
TERMINATED
Efficacy and Safety of the Combination of Trastuzumab Plus TUCAtinib Plus viNorelbine in Patients With HER2-positive Non-resectable Locally Advanced or Metastatic Breast CancerNCT05583110 · lead sponsor · 2023-03-08
TERMINATED
Three Antidiarrheal Strategies in HER2+/HR+ Early Breast Cancer Patients Treated With Extended Adjuvant NeratinibNCT05252988 · lead sponsor · 2022-08-31
ACTIVE_NOT_RECRUITING
Trastuzumab + Alpelisib +/- Fulvestrant vs Trastuzumab + CT in Patients With PIK3CA Mutated Previously Treated HER2+ Advanced BrEasT Cancer (ALPHABET)NCT05063786 · lead sponsor · 2021-09-14
ACTIVE_NOT_RECRUITING
Characterization of Innate Immune System in Patients With Luminal Advanced Breast CancerNCT04370522 · lead sponsor · 2021-05-21
TERMINATED
Neoadjuvant Study Chemotherapy vs Letrozole + Abemaciclib in HR+/HER2- High/Intermediate Risk Breast Cancer PatientsNCT04293393 · lead sponsor · 2020-10-02
ACTIVE_NOT_RECRUITING
Registry Study of Pregnancy and Breast CancerNCT04603820 · lead sponsor · 2019-11-18
ACTIVE_NOT_RECRUITING
Study on the Progress of Breast Cancer Cases in Males and the Assessment of Relapse RiskNCT03800355 · lead sponsor · 2018-09-14
COMPLETED
Unraveling KAdcyla Resistance In Human Epidermal Growth Factor Receptor 2(HER2) Positive Advanced Breast Cancer (KATIA)NCT03829306 · lead sponsor · 2018-06-12
COMPLETED
Healthy Lifestyles and Quality of Life in Women With Breast CancerNCT04379908 · lead sponsor · 2017-11-07
COMPLETED
Analysis of Olaparib Response in Patients With BRCA1 and/or 2 Promoter Methylation Diagnosed of Advanced Breast CancerNCT03205761 · lead sponsor · 2017-10-23
COMPLETED
Trial to Evaluate Efficacy and Safety of Pembrolizumab and Gemcitabine in HER2-negative ABCNCT03025880 · lead sponsor · 2017-06-28
COMPLETED
Retrospective Observational Study About Evolution of Patients With Breast Cancer in Hospitals From GEICAM GroupNCT03210974 · lead sponsor · 2016-06-03
COMPLETED
Effect of Physical Exercise on Tumor Proliferation of Luminal B Breast Cancer PatientsNCT03860740 · lead sponsor · 2016-06-01
COMPLETED
Fulvestrant (F)+Placebo vs F+Palbociclib First Line for Postmenopausal Hormone Receptor+ Advanced Breast CancerNCT02690480 · lead sponsor · 2016-02-17
UNKNOWN
Study of LDE225 (Sonidegib) in Combination With Docetaxel in Triple Negative (TN) Advanced Breast Cancer (ABC) PatientsNCT02027376 · lead sponsor · 2014-05-01
COMPLETED
Phase III Palbociclib With Endocrine Therapy vs. Capecitabine in HR+/HER2- MBC With Resistance to Aromatase InhibitorsNCT02028507 · lead sponsor · 2014-03-13
COMPLETED
Phase III to Evaluate Patient´s Preference of Subcutaneous Trastuzumab vs Intravenous in HER2+ Advanced Breast CancerNCT01875367 · lead sponsor · 2013-09-18
COMPLETED
Evaluation of Hypertension as a Predictor of Efficacy Bevacizumab in Metastatic Breast Cancer and Colorectal CancerNCT01733628 · lead sponsor · 2012-10-23
COMPLETED
A Combined GWAS and miRNA for the Identification of Bevacizumab Response Predictors in Metastatic Breast CancerNCT01598285 · lead sponsor · 2012-04-18
TERMINATED
Neoadjuvant Treatment With Nab-paclitaxel for Patients With Stage II and III Luminal Breast CancerNCT01565499 · lead sponsor · 2012-04-17
COMPLETED
Dasatinib In Combination With Trastuzumab And Paclitaxel In First Line Treatment Of Her2-Positive MBC PatientsNCT01306942 · lead sponsor · 2011-07-01
COMPLETED
Incidence of Chemotherapy-Induced Nausea and Vomiting Associated With Docetaxel-Cyclophosphamide in Early Breast Cancer.NCT01298193 · lead sponsor · 2011-05-01
COMPLETED
Evaluation of Degree of Conversion of HER2 Receptor Between Primary Breast Cancer and MetastasisNCT01377363 · lead sponsor · 2009-12-11
COMPLETED
Trastuzumab Versus Lapatinib as Neoadjuvant Treatment for Her2+ PatientsNCT00841828 · lead sponsor · 2009-02-01
COMPLETED
Bevacizumab + Endocrine Treatment vs Endocrine Treatment as First Line in Postmenopausal WomenNCT00545077 · lead sponsor · 2007-11-06
COMPLETED
Fulvestrant (Faslodex) + Anastrozole (Arimidex) vs AnastrozoleNCT00543127 · lead sponsor · 2007-11-01
TERMINATED
Study of the Utility of the BOMET-QOL Questionnaire Patients With Breast Cancer and Bone MetastasisNCT03847220 · lead sponsor · 2007-10-23
COMPLETED
Capecitabine Plus Radiotherapy for Local Relapse Breast Cancer With Negative Her2 TumoursNCT00434941 · lead sponsor · 2007-09-01
TERMINATED
Selective Neoadjuvant Treatment According to Immunohistochemical Subtype for HER2 Negative Breast Cancer PatientsNCT00432172 · lead sponsor · 2007-04-24
COMPLETED
Caelyx, Cyclophosphamide and Herceptin in Patients With Metastatic Breast CancerNCT00258960 · lead sponsor · 2006-02-15
COMPLETED
Maintenance Treatment With Capecitabine Versus Observation in Breast Cancer PatientsNCT00130533 · lead sponsor · 2006-01-01
COMPLETED
Benefit of Adding Trastuzumab to Second Line Chemotherapy in Breast Cancer Patients Previously Treated With TrastuzumabNCT00130507 · lead sponsor · 2005-11-04
TERMINATED
EC Followed Docetaxel Versus ET Followed Capecitabine as Adjuvant Chemotherapy for Node Positive Operable Breast CancerNCT00129935 · lead sponsor · 2004-02-01
COMPLETED
Neoadjuvant Chemotherapy With Myocet/Taxotere/Herceptin for HER2 Positive Breast Cancer PatientsNCT00129896 · lead sponsor · 2004-01-01
COMPLETED
FAC Versus FAC Plus Weekly Paclitaxel as Adjuvant Treatment of Node Negative High Risk Breast Cancer PatientsNCT00129389 · lead sponsor · 2003-09-19
COMPLETED
Gemcitabine, Doxorubicin and Paclitaxel (GAT) as Neoadjuvant Treatment of Breast Cancer PatientsNCT00128856 · lead sponsor · 2003-03-01
COMPLETED
Doxorubicin and Cyclophosphamide (AC) Followed by Weekly Docetaxel as Neoadjuvant Treatment of Breast Cancer PatientsNCT00129376 · lead sponsor · 2003-02-01
COMPLETED
Maintenance Treatment With Liposomal Doxorubicin (Caelyx) in Metastatic Breast Cancer PatientsNCT00128778 · lead sponsor · 2002-10-28
COMPLETED
Zoledronic Acid Administration to Metastatic Breast Cancer Patients With Non-symptomatic Bone LesionsNCT00130494 · lead sponsor · 2002-08-29
TERMINATED
Exemestane Versus Anastrozole as First Line Hormone Therapy in Postmenopausal Metastatic Breast Cancer PatientsNCT00128843 · lead sponsor · 2001-08-01
COMPLETED
Vinorelbine Versus Gemcitabine Plus Vinorelbine in Metastatic Breast Cancer PatientsNCT00128310 · lead sponsor · 2001-01-18
COMPLETED
Pamidronate Administration in Breast Cancer Patients With Bone MetastasesNCT00128297 · lead sponsor · 2000-10-18
COMPLETED
Fluorouracil, Epirubicin, and Cyclophosphamide Alone or Followed by Paclitaxel for Early Breast CancerNCT00129922 · lead sponsor · 1999-11-01
COMPLETED
Docetaxel, Doxorubicin (A), Cyclophosphamide (C) (TAC) vs 5-Fluorouracil, A, C (5FAC) Breast Cancer Adjuvant TreatmentNCT00121992 · lead sponsor · 1999-07-01
COMPLETED
Nadunolimab in Combination With Gemcitabine Plus Carboplatin in Patients With Advanced Triple Negative Breast Cancer.NCT05181462 · collaborator · 2022-01-11
COMPLETED
A Study of Trastuzumab Deruxtecan (T-DXd) Versus Trastuzumab Emtansine (T-DM1) in High-risk HER2-positive Participants With Residual Invasive Breast Cancer Following Neoadjuvant Therapy (DESTINY-Breast05)NCT04622319 · collaborator · 2020-12-04
ACTIVE_NOT_RECRUITING
A Clinical Trial to Assess the Safety of 0.005 % Estriol Vaginal Gel in Hormone Receptor-Positive Postmenopausal Women With Early Stage Breast Cancer in Treatment With Aromatase Inhibitor in the Adjuvant SettingNCT02413008 · collaborator · 2015-10-16
COMPLETED
A Prospective Observational Study of Clinical Outcomes for the NanoString® Technologies Prosigna Gene Signature AssayNCT01899079 · collaborator · 2013-06-01
COMPLETED

Sponsor roles

lead sponsor50
collaborator4
Advertisement

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.